2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
It's been a few years since these biotech stocks made their debut on the public markets, but they're more popular than ever right now. Investors who held on since Day One have outperformed, and those just hearing about these drugmakers now want to know if they can keep climbing.
Data source: Yahoo! Finance.
Let's look at what these companies have done with cash raised in their initial public offerings (IPOs) to see if their shares can continue to outperform for investors.
Source Fool.com
